Literature DB >> 3576659

Dual effects of carbamazepine-phenytoin interaction.

J J Zielinski, D Haidukewych.   

Abstract

By intrapatient comparison at constant phenytoin (PHT) dose, the effect of increased carbamazepine (CBZ) dose was studied in 32 epileptic outpatients treated with a combination of PHT and CBZ. The mean PHT plasma concentration, as well as the concentration/dose ratio for PHT, became significantly higher secondary to increased doses of CBZ (14.1 +/- 3.5 vs. 19.3 +/- 3.6 micrograms/ml and 2.8 +/- 1.0 vs. 3.9 +/- 1.4 micrograms/ml plasma per milligram/kilogram daily dose, respectively; p less than 0.001). Concomitantly, in spite of CBZ dose higher by 17.6%, the CBZ concentration increased by only 6.4%, and the CBZ concentration/dose ratio actually decreased by 10%. In contrast, by intrapatient comparison at constant CBZ dose, the effect of reduced PHT dose on CBZ was studied in 22 patients. The mean CBZ plasma concentration as well as the concentration/dose ratio for CBZ appeared significantly higher, with a concomitant reduction of PHT (6.7 +/- 1.6 vs. 8.6 +/- 1.6 micrograms/ml and 0.37 +/- 0.1 vs. 0.49 +/- 0.2 micrograms/ml plasma per milligram/kilogram daily dose, respectively; p less than 0.001). This simultaneous dual effect--inhibition of PHT metabolism by CBZ and induction of CBZ metabolism by PHT--can result in PHT intoxication along with a fall in CBZ plasma concentration to a subtherapeutic range. This effect may be avoided or reduced if the PHT concentration is adjusted to approximately 13 micrograms/ml before CBZ is added or increased.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3576659     DOI: 10.1097/00007691-198703000-00004

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

Review 1.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Pharmacokinetic simulation of fatal carbamazepine intoxication in 23-month old child following phenytoin discontinuation.

Authors:  Jineane V Venci; Meghan M Rowcliffe; Lance Wollenberg; Michelle M Rainka; Fran M Gengo
Journal:  Forensic Sci Med Pathol       Date:  2012-08-23       Impact factor: 2.007

Review 3.  Differential kinetics of phenytoin in elderly patients.

Authors:  K A Bachmann; R J Belloto
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

Review 4.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 5.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

6.  Inhibitory effects of wogonin on catalytic activity of cytochrome P450 enzyme in human liver microsomes.

Authors:  Tingting Li; Ning Li; Qinglong Guo; Hui Ji; Di Zhao; Shan Xie; Xiaonan Li; Zhixia Qiu; Deen Han; Xijing Chen; Qidong You
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-06-29       Impact factor: 2.441

7.  Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy.

Authors:  P N Patsalos; J S Duncan; S D Shorvon
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

8.  Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin.

Authors:  M L Lai; T S Lin; J D Huang
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 9.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.